Nifedipine Soft Capsules

1. This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm. 2. This product can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. 3. This product can relax peripheral resistance vessels, reduce peripheral resistance, and can reduce systolic and diastolic blood pressure, reducing cardiac afterload. 4. This product can delay the sinus node function and atrioventricular conduction of the isolated heart; electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinus node, and slowing down the sinus node rate. Carcinogenicity, mutagenicity and reproductive toxicity No carcinogenic effect. No mutagenicity. High-dose application can reduce the fertility of female mice; can cause teratogenesis; can cause abortion (increased drug absorption rate in fetal mice, increased fetal mouse mortality, and decreased survival rate of newborn mice). Pregnant monkeys taking 2/3 to 2 times the maximum human dose can cause small placentas and chorionic dysgenesis; rats taking 3 times the maximum human dose can cause prolonged pregnancy. The effect on human fertility is still unclear.

Chemical name: 2,6-dimethyl-4(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester. Molecular formula: C17H18N2O6. Molecular weight: 346.34.

This product is a capsule containing yellow viscous liquid.

Angina: variant angina; unstable angina; chronic stable angina. Hypertension (alone or in combination with other antihypertensive drugs).

1 The dose of nifedipine should be gradually adjusted according to the patient's tolerance and control of angina pectoris. Overdose of nifedipine can cause hypotension. 2 Start with a small dose, usually 10 mg/time, 3 times a day; the commonly used maintenance dose is 10-20 mg/time, 3 times a day. Some patients with obvious coronary spasm can use 20-30 mg/time, 3-4 times a day. The maximum dose should not exceed 120 mg/day. If the condition is urgent, 10 mg/time can be chewed or taken sublingually, and the decision to re-administer the drug depends on the patient's response to the drug. 3 It usually takes 7-14 days to adjust the dose. If the patient's symptoms are obvious and the condition is urgent, the dose adjustment period can be shortened. Depending on the patient's response to the drug, the frequency of attacks and the dose of sublingual nitroglycerin, the dose of nifedipine can be adjusted from 10-20 mg to 30 mg/time, 3 times a day within 3 days. 4 For hospitalized patients under strict monitoring, the dose can be increased by 10 mg every 4 to 6 hours, depending on the control of angina pectoris or ischemic arrhythmias.

1. The dose of nifedipine should be gradually adjusted according to the patient's tolerance and control of angina pectoris. Overdose of nifedipine can cause hypotension. 2. Start with a small dose, usually 10 mg/time, 3 times a day; the commonly used maintenance dose is 10-20 mg/time, 3 times a day. Some patients with obvious coronary spasm can use 20-30 mg/time, 3-4 times a day. The maximum dose should not exceed 120 mg/day. If the condition is urgent, 10 mg/time can be chewed or taken sublingually, and the decision to re-administer the drug depends on the patient's response to the drug. 3. It usually takes 7-14 days to adjust the dose. If the patient's symptoms are obvious and the condition is urgent, the dose adjustment period can be shortened. According to the patient's response to the drug, the frequency of attacks and the dose of sublingual nitroglycerin, the dose of nifedipine can be adjusted from 10-20 mg to 30 mg/time, 3 times a day within 3 days. 4. For hospitalized patients under strict monitoring, the dose can be increased by 10 mg every 4 to 6 hours, depending on the control of angina pectoris or ischemic arrhythmias.

It is contraindicated in patients allergic to nifedipine.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. Nitrates are used in combination with this product to control angina attacks and are well tolerated. 2. Most patients with beta-receptor blockers have good tolerance and efficacy when using this product in combination, but some patients may induce and aggravate hypotension, heart failure and angina. 3. Digitalis This product may increase blood digoxin concentrations, suggesting that the blood concentration of digoxin should be monitored when using it for the first time, adjusting the dose or stopping this product. 4. When drugs with high protein binding rates such as dicoumarins, phenytoin sodium, quinidine, quinine, warfarin, etc. are used with this product, the free concentrations of these drugs often change. 5. When cimetidine is used with this product, the peak plasma concentration of this product increases, so pay attention to adjusting the dose.

Keep in a light-proof and airtight container.

5mg

36 months

Shanghai Sine Yanan Pharmaceutical Co., Ltd.

• Founded in:

  2003-08-06

• Address:

  No. 298, Xinggong Road, Tinglin Town, Jinshan District, Shanghai

• Tax NO.:

  91310116753162119M

• Registered Funds:

  6.46 million yuan

• Email:

  Log in to view